A Preliminary Clinical Trial to Evaluate Cu-NOTA-Trastuzumab As a Positron Emission Tomography Imaging Agent in Patients with Breast Cancer

Overview

Journal EJNMMI Res

Date 2021 Jan 21

PMID 33475899

Citations 12

Authors

Inki Lee

Ilhan Lim

Byung Hyun Byun

Byung Il Kim

Chang Woon Choi

Sang-Keun Woo

Kwang Il Kim

Kyo Chul Lee

Joo Hyun Kang

Min-Ki Seong

Hyun-Ah Kim

Woo Chul Noh

Sang Moo Lim

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to evaluate both the biodistribution and safety of Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients with breast cancer.

Methods: PET images at 1, 24, and 48 h after 296 MBq of Cu-NOTA-Trastuzumab injection were obtained from seven patients with breast cancer. Both the primary tumors' and metastatic lesions' maximum standardized uptake value (SUV) was evaluated. The mean SUV (SUV) was evaluated in the other organs, including the blood pool, liver, kidney, muscle, spleen, bladder, and the lungs, as well as the bones. Moreover, the internal radiation dosimetry was calculated using the OLINDA/EXM software. Safety was assessed based on feedback regarding adverse reactions and safety-related issues within 1 month after Cu-NOTA-Trastuzumab administration.

Results: Cu-NOTA-Trastuzumab PET images showed that the overall SUV values in each organ negatively correlated with time. The liver's average SUV values were measured at 5.3 ± 0.7, 4.8 ± 0.6, and 4.4 ± 0.5 on 1 h, 24 h, and 48 h after injection, respectively. The average SUV blood values were measured at 13.1 ± 0.9, 9.1 ± 1.2, and 7.1 ± 1.9 on 1 h, 24 h, and 48 h after injection, respectively. The SUV of HER2-positive tumors was relatively higher than HER2-negative tumors (8.6 ± 5.1 and 5.2 ± 2.8 on 48 h after injection, respectively). Tumor-to-background ratios were higher in the HER2-positive tumors than in the HER2-negative tumors. No adverse events related to Cu-NOTA-Trastuzumab were reported. The calculated effective dose with a 296 MBq injection of Cu-NOTA-Trastuzumab was 2.96 mSv. The highest absorbed dose was observed in the liver (0.076 mGy/MBq), followed by the spleen (0.063 mGy/MBq), kidney (0.044 mGy/MBq), and heart wall (0.044 mGy/MBq).

Conclusions: Cu-NOTA-Trastuzumab showed a specific uptake at the HER2-expressing tumors, thus making it a feasible and safe monitoring tool of HER2 tumor status in patients with breast cancer.

Trial Registration: CRIS, KCT0002790. Registered 02 February 2018, https://cris.nih.go.kr.

Citing Articles

Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.

Krecisz P, Stefanska K, Studzinski J, Pitucha M, Czylkowska A, Szymanski P J Med Chem. 2025; 68(3):2356-2376.

PMID: 39895089 PMC: 11831595. DOI: 10.1021/acs.jmedchem.4c02885.

Novel Molecular Classification of Breast Cancer with PET Imaging.

Toan N Medicina (Kaunas). 2025; 60(12.

PMID: 39768978 PMC: 11678748. DOI: 10.3390/medicina60122099.

Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.

Gui X, Liang X, Guo X, Yang Z, Song G Oncologist. 2024; 30(1).

PMID: 39083323 PMC: 11783325. DOI: 10.1093/oncolo/oyae188.

Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis.

Ahmadi M, Ritter C, von Woedtke T, Bekeschus S, Wende K Chem Sci. 2024; 15(6):1966-2006.

PMID: 38332833 PMC: 10848714. DOI: 10.1039/d3sc05539f.

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.

Castorina L, Comis A, Prestifilippo A, Quartuccio N, Panareo S, Filippi L J Clin Med. 2024; 13(1).

PMID: 38202160 PMC: 10779934. DOI: 10.3390/jcm13010154.

References

Mortimer J, Shively J . Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA. J Nucl Med. 2018; 60(1):23-25. DOI: 10.2967/jnumed.118.220905. View

Houssami N, Macaskill P, Balleine R, Bilous M, Pegram M . HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat. 2011; 129(3):659-74. DOI: 10.1007/s10549-011-1632-x. View

Gaykema S, de Jong J, Perik P, Brouwers A, Schroder C, Oude Munnink T . (111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014; 13(5). DOI: 10.2310/7290.2014.00011. View

De Silva R, Jain S, Lears K, Chong H, Kang C, Sun X . Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development. Nucl Med Biol. 2012; 39(8):1099-104. PMC: 3470735. DOI: 10.1016/j.nucmedbio.2012.05.009. View

Dearling J, Voss S, Dunning P, Snay E, Fahey F, Smith S . Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011; 38(1):29-38. PMC: 3032412. DOI: 10.1016/j.nucmedbio.2010.07.003. View

Falzone L, Salomone S, Libra M . Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018; 9:1300. PMC: 6243123. DOI: 10.3389/fphar.2018.01300. View

Mortimer J, Bading J, Colcher D, Conti P, Frankel P, Carroll M . Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med. 2013; 55(1):23-9. PMC: 4084518. DOI: 10.2967/jnumed.113.122630. View

Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X . Construction of I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer. 2020; 23(4):614-626. DOI: 10.1007/s10120-019-01035-6. View

Kreutzfeldt J, Rozeboom B, Dey N, De P . The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020; 10(4):1045-1067. PMC: 7191090. View

10.

OWEN Jr C, HAZELRIG J . Metabolism of cu-64-labeled copper by the isolated rat liver. Am J Physiol. 1966; 210(5):1059-64. DOI: 10.1152/ajplegacy.1966.210.5.1059. View

11.

Yan M, Schwaederle M, Arguello D, Millis S, Gatalica Z, Kurzrock R . HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015; 34(1):157-64. PMC: 4368842. DOI: 10.1007/s10555-015-9552-6. View

12.

Ulaner G, Hyman D, Lyashchenko S, Lewis J, Carrasquillo J . 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clin Nucl Med. 2017; 42(12):912-917. PMC: 5708879. DOI: 10.1097/RLU.0000000000001820. View

13.

Woo S, Jang S, Seo M, Park J, Kim B, Kim E . Development of Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. J Nucl Med. 2018; 60(1):26-33. DOI: 10.2967/jnumed.118.210294. View

14.

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K . (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015; 5:8. PMC: 4385241. DOI: 10.1186/s13550-015-0082-6. View

15.

Mortimer J, Bading J, Park J, Frankel P, Carroll M, Tran T . Tumor Uptake of Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. J Nucl Med. 2017; 59(1):38-43. PMC: 5750523. DOI: 10.2967/jnumed.117.193888. View

16.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y . 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013; 54(11):1869-75. DOI: 10.2967/jnumed.112.118612. View

17.

Branco F, Machado D, Silva F, Andre S, Catarino A, Madureira R . Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am J Transl Res. 2019; 11(9):6110-6116. PMC: 6789273. View

18.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T . 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Ann Oncol. 2017; 28(8):2028-2029. DOI: 10.1093/annonc/mdx227. View

19.

Laforest R, Lapi S, Oyama R, Bose R, Tabchy A, Marquez-Nostra B . [Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Mol Imaging Biol. 2016; 18(6):952-959. PMC: 5096950. DOI: 10.1007/s11307-016-0951-z. View

20.

Chen W, Li X, Zhu L, Liu J, Xu W, Wang P . Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer. Cancer Biol Med. 2017; 14(3):271-280. PMC: 5570603. DOI: 10.20892/j.issn.2095-3941.2017.0044. View